BiomX will share their latest data at Targeting Phage Therapy 2023

Iddo Nadav Weiner, VP of Research at BiomX, Israel will present a short oral talk entitled “A Phase 1b/2a Randomized, Double-blind, Placebo-controlled Study Evaluating Nebulized Phage Therapy in Cystic Fibrosis Subjects With Chronic Pseudomonas Aeruginosa Pulmonary Infection ” during Targeting Phage Therapy 2023 on June 1-2 in Paris.

Dr. Weiner will describe the development of a phage cocktail designed to efficiently target a wide range of P. aeruginosa strains. The phage cocktail when administered to nine cystic fibrosis patients chronically infected with P. aeruginosa in a phase 1b/2a double-blinded placebo-controlled clinical trial, was demonstrated to be safe and well-tolerated.

Furthermore, patients treated with phage showed a dramatic reduction in P. aeruginosa sputum density compared to the placebo group. 

Join Targeting Phage Therapy Conference to learn more about Dr. Weiner’s and this BiomX phage cocktail.

Conference program.

Abstract submission is still open for phage innovations/research.

Targeting Phage Therapy 2023
6th World Conference
June 1-2, 2023 – Paris, France
LinkedIn | Facebook| Website